Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017;7(2):275-278.
doi: 10.3233/JPD-161042.

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa

Ahmed A Othman  1 , Matthew Rosebraugh  1 , Krai Chatamra  2 , Charles Locke  1 , Sandeep Dutta  3
Affiliations
Free PMC article
Clinical Trial

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa

Ahmed A Othman et al. J Parkinsons Dis. 2017.
Free PMC article

Abstract

In a double-blind, double-dummy, double-titration Phase 3 trial in advanced Parkinson's disease (PD) patients, the efficacy and safety of Levodopa-carbidopa intestinal gel (LCIG) infusion were characterized relative to immediate-release oral levodopa-carbidopa (LC-oral) treatment. We present in this report the comparative pharmacokinetic profiles of LCIG and LC-oral from this pivotal study. The results presented in this report clearly demonstrate that LCIG results in lower variability and fluctuations in levodopa and carbidopa plasma concentrations compared to LC-oral. The superior pharmacokinetic profiles with LCIG were consistent with its improved efficacy compared to LC-oral as demonstrated in this study.

Keywords: Parkinson’s disease; levodopa/carbidopa intestinal gel; movement disorders; pharmacokinetics.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Levodopa and Carbidopa Plasma Concentrations for Subjects with Advanced Parkinson’s Disease Receiving LCIG or LC-Oral. Each color represents a different subject for each treatment. LCIG = levodopa-carbidopa intestinal gel. LC-Oral = oral levidopa-carbidopa.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Olanow CW, Watts RL, & Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment guidelines. Neurology, 56, S1–S88. - PubMed
    1. LeWitt PA, Nelson MV, Berchou RC, Galloway MP, Kesaree N, Kareti D, & Schlick P (1989) Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): Clinical and pharmacokinetic studies. Neurology 39, 45–53; discussion 59. - PubMed
    1. Nyholm D, Lennernas H, Gomes-Trolin C, & Aquilonius SM (2002) Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson’s disease on individual drug combinations. Clin Neuropharmacol, 25, 89–96. - PubMed
    1. Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, & Aquilonius SM (2003) Optimizing levodopa pharmacokinetics: Intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol, 26, 156–163. - PubMed
    1. Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, & Othman AA (2013) Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J 15, 316–323. - PMC - PubMed

Publication types